NCT03701438View on ClinicalTrials.gov

Immune Response to Influenza Vaccine in Adults With B-cell Malignancies Treated With Idelalisib

TerminatedOBSERVATIONAL
Enrollment

2

Participants

Timeline

Start Date

October 23, 2018

Primary Completion Date

October 9, 2019

Study Completion Date

October 9, 2019

Conditions
B-cell Malignancies
Interventions
BIOLOGICAL

Influenza Vaccine

Administered per standard of care using a vaccine licensed and recommended in the site's country

Trial Locations (2)

28034

Hospital Universitario Ramon y Cajal, Madrid

100 34

Fakultni nemocnice Kralovske Vinohrady, Interni hematologicka klinika, Prague

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
lead

Gilead Sciences

INDUSTRY